灌注CT评估胰腺导管腺癌新辅助放化疗反应:初步经验
前瞻性研究纳入21例活检证实的胰腺导管腺癌患者,在新辅助放化疗前后行灌注CT,量化血流量、血容量和渗透表面面积乘积。基线血流量在反应者高于非反应者,反应者治疗后灌注参数升高;灌注CT可能有助于预测组织病理学反应。
要点
- 基线血流量较高的胰腺导管腺癌患者对新辅助放化疗的组织病理学反应更好。
- 反应者放化疗后血流量较治疗前升高,非反应者变化未达统计学显著。
- RECIST和CA 19-9与灌注参数及组织病理学反应均无相关性。
核心结论
- 灌注CT可能有助于预测胰腺导管腺癌对新辅助放化疗的组织病理学反应。
研究设计与样本
- 前瞻性研究,2016年6月至2018年5月招募活检证实的胰腺导管腺癌患者,最终21例(中位年龄68岁,IQR 65-72岁,8例男性)在新辅助放化疗前行动态灌注(双源)CT,所有患者均行胰腺切除术,其中18例在放化疗后行灌注CT。
关键影像表现/征象
- 反应者基线血流量中位数44(IQR 39-56)mL/100 g/min,高于非反应者的28(IQR 16-52)mL/100 g/min(P = .04)。
- 反应者与非反应者基线血容量中位数分别为4.3(IQR 3.5-6.9)与2.0(IQR 1.6-6.5)mL/100 g(P = .15),两组相似。
- 反应者与非反应者基线渗透表面面积乘积中位数分别为25(IQR 21-30)与20(IQR 10-34)mL/100 g/min(P = .31),两组相似。
- 反应者放化疗后血流量中位数54(IQR 42-73)mL/100 g/min,较治疗前的43(IQR 28-53)mL/100 g/min升高(P = .04)。
- 非反应者放化疗后血流量中位数43(IQR 28-53)mL/100 g/min,与治疗前的33(IQR 16-52)mL/100 g/min相比变化未达统计学显著(P = .06)。
诊断标准与关键数值
- 根据治疗反应将患者分为反应者(n=10)和非反应者(n=11)。
- RECIST与血流量无相关性(r = 0.05,P = .84,95%CI:-0.40,0.48)。
- CA 19-9与血流量无相关性(r = 0.06,P = .78,95%CI:-0.39,0.49)。
- RECIST与组织病理学反应无相关性(r = 0.16,P = .47,95%CI:-0.3,0.57)。
- CA 19-9与组织病理学反应无相关性(r = 0.09,P = .71,95%CI:-0.37,0.51)。
临床应用与阅片要点
- 灌注CT可量化肿瘤血流量、血容量和渗透表面面积乘积,基线血流量可能有助于预测胰腺导管腺癌新辅助放化疗的组织病理学反应。
- RECIST和CA 19-9与灌注参数及组织病理学反应均无相关性,评估治疗反应时需注意其局限性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BackgroundChange in tumor size at CT is insufficient for reliable assessment of treatment response after neoadjuvant chemotherapy and radiation therapy (CRT) and shows poor correlation with histologic grading of response.PurposeTo investigate the use of perfusion CT to predict the response of pancreatic ductal adenocarcinoma (PDA) to CRT.Materials and MethodsBetween June 2016 and May 2018, study participants with biopsy-proven PDA were prospectively recruited to undergo perfusion CT before and after planned CRT. Blood flow (BF), blood volume (BV), and permeability-surface area product (PSP) were quantified from CT images. Participants were categorized into responders and nonresponders according to therapy response. The Mann-Whitney test was used to compare the baseline perfusion values between responders and nonresponders, and the Wilcoxon matched-pairs signed rank test was used to compare perfusion values before and after CRT.ResultsThe final cohort of 21 participants (median age, 68 years; interquartile range [IQR], 65-72 years; eight men) underwent dynamic perfusion (dual-source) CT before neoadjuvant CRT. All participants underwent pancreatectomy. Eighteen participants underwent post-CRT perfusion CT. Baseline BF was higher in responders (n = 10) than in nonresponders (n = 11) (median, 44 [IQR, 39-56] vs 28 [IQR, 16-52] mL/100 g/min; P = .04), while BV and PSP were similar between groups (median BV, 4.3 [IQR, 3.5-6.9] vs 2.0 [IQR, 1.6-6.5] mL/100 g, P = .15; median PSP, 25 [IQR, 21-30] vs 20 [IQR, 10-34] mL/100 g/min, P = .31). Response Evaluation Criteria in Solid Tumors (RECIST) and carbohydrate antigen (CA) 19-9 showed no correlation with perfusion parameters (eg, RECIST and BF: r = 0.05, P = .84, 95% confidence interval [CI]: -0.40, 0.48; CA 19-9 and BF: r = 0.06, P = .78, 95% CI: -0.39, 0.49) or histopathologic response (r = 0.16, P = .47, 95% CI: -0.3, 0.57 and r = 0.09, P = .71, 95% CI: -0.37, 0.51, respectively). For responders, perfusion parameters increased after CRT (eg, median BF, 54 [IQR, 42-73] vs 43 [IQR, 28-53] mL/100 g/min; P = .04). The perfusion change in nonresponders was not significant (median BF, 43 [IQR, 28-53] vs 33 [IQR, 16-52] mL/100 g/min; P = .06).ConclusionPerfusion CT may be useful in helping predict the histopathologic response to therapy in pancreatic ductal adenocarcinoma.© RSNA, 2019See also the editorial by Sinitsyn in this issue.
引用
- Hamdy A, Ichikawa Y, Toyomasu Y, et al. Perfusion CT to Assess Response to Neoadjuvant Chemotherapy and Radiation Therapy in Pancreatic Ductal Adenocarcinoma: Initial Experience. Radiology. 2019. PMID: 31287389. doi:10.1148/radiol.2019182561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。